Trial Profile
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2023
Price :
$35
*
At a glance
- Drugs Mammaglobin A DNA vaccine (Primary) ; Antineoplastics
- Indications Breast cancer
- Focus Adverse reactions
- 10 Feb 2023 Planned End Date changed from 31 Jan 2029 to 31 Aug 2028.
- 10 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2023 Planned End Date changed from 31 Jan 2028 to 31 Jan 2029.